Physician profile
Kevan Herold
NPI 1083709463
$260,542.92
in general payments reported to CMS, 2019-2025
11 companies · $96K in 2025
The $96K reported for 2025 was more than what 98% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,980 · 2020: $7,044 · 2021: $7,480 · 2023: $78K · 2024: $68K · 2025: $96K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $106K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $80K · Travel and Lodging: $53K · Food and Beverage: $2,041.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $106,401.91 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $80,145.87 |
| Travel and Lodging | $53,449.97 |
| Food and Beverage | $2,041.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $204,489.37 | 2023-2025 | |
| Genzyme Corporation | $24,703.00 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $6,378.70 | 2020-2024 | |
| Merck Sharp & Dohme LLC | $5,100.00 | 2021 | |
| Sanofi US Services INC. | $4,122.00 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $4,034.01 | 2023 | |
| Pfizer INC. | $3,980.00 | 2019 | |
| Biogen, INC. | $3,675.00 | 2020 | |
| Novo Nordisk As | $3,542.50 | 2021-2025 | |
| Glaxosmithkline, LLC. | $518.34 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevan Herold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.